Pay in 4 interest-free payments of $7.42 Learn more
Ships within 48 hours · Estimated delivery Aug 30 - Sep 4
Question 1: Is the medication another GLP-1 receptor agonist
Once-weekly semaglutide 0.5 mg and 1 mg were compared with dulaglutide 0.75 mg and 1.5 mg, respectively, in the SUSTAIN 7 clinical trial, and were associated with greater reductions in HbA1c and body weight in people with type 2 diabetes with inadequate glycaemic control on metformin, with a subsequent long-term cost-effectiveness analysis in the UK demonstrating that these clinical benefits translated to improved life expectancy, quality of life and cost savings over patients lifetimes [13, 14]
Check out the sites supporting obesity trials in the US The Next Chapter of the GLP-1 Story GLP-1 drugs have already reshaped obesity treatment
If upcoming maintenance data in is consistent with induction data, then obefazimod will truly take form
